166 related articles for article (PubMed ID: 3516395)
21. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
[TBL] [Abstract][Full Text] [Related]
22. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
[TBL] [Abstract][Full Text] [Related]
23. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
26. [Cytosine-arabinoside in high doses in refractory acute granulocytic leukemia. Apropos of 17 cases].
Jouet JP; Simon M; Fenaux P; Pollet JP; Bauters F
Nouv Rev Fr Hematol (1978); 1985; 27(3):169-73. PubMed ID: 3862072
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
[TBL] [Abstract][Full Text] [Related]
28. [High-dose cytarabine treatment: a promising therapy modality in acute resistant myeloid leukemias in recurrence].
Meusers P; Heidemann H; Lunscken C; Uppenkamp M; Zou P; Brittinger G
Onkologie; 1985 Feb; 8(1):16, 18-9. PubMed ID: 3885115
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of amsacrine gluconate in refractory leukemia.
Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948
[TBL] [Abstract][Full Text] [Related]
31. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
Hiraoka A; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):93-9. PubMed ID: 9987504
[TBL] [Abstract][Full Text] [Related]
32. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
33. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
34. High dose cytarabine: a review.
Bolwell BJ; Cassileth PA; Gale RP
Leukemia; 1988 May; 2(5):253-60. PubMed ID: 3287015
[TBL] [Abstract][Full Text] [Related]
35. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
[No Abstract] [Full Text] [Related]
36. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
Vogler WR; Trulock PD
Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Tschopp L; von Fliedner VE; Sauter C; Maurice P; Gratwohl A; Fopp M; Cavalli F
J Clin Oncol; 1986 Mar; 4(3):318-24. PubMed ID: 3456425
[TBL] [Abstract][Full Text] [Related]
39. AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.
Boccia R; Zighelboim J; Champlin RE; Kim CC; Gale RP
Med Pediatr Oncol; 1984; 12(3):178-9. PubMed ID: 6587178
[TBL] [Abstract][Full Text] [Related]
40. High dose cytarabine in acute myelogenous leukemia.
Zittoun R
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():38-42. PubMed ID: 2653516
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
